Mr. Huang joined CASI in Januaury 2024 as Global CCO and GM of CASI China.

Mr. Huang has 27 years of business operations and international management experience in the pharmaceutical industry. Prior to Joining CASI, Mr. Huang held the position of CEO at Fosun Kite, where he led the approval and commercialization of China's first CAR-T cell therapy drug. Thus, he was known as a pioneer in the commercialization of CAR-T therapy in China.

He holds bachelor degree in biochemistry from Lanzhou University and a Bi-MBA degree from Peking University.